Company: HCTI
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001213900-25-109581
Chunk: 83

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 83
---
 include
all of the information and notes required by GAAP for audited financial statements. The year-end December 31, 2024 condensed consolidated
balance sheet data included herein was derived from audited financial statements. In the opinion of management, the accompanying unaudited
condensed consolidated financial statements contain all adjustments, consisting of items of a normal and recurring nature, necessary
to present fairly our financial position as of September 30, 2025, the results of operations, comprehensive loss, stockholders’
deficit, and cash flows for the nine months ended September 30, 2025 and 2024. The results of operations for the nine months ended September
30, 2025 and 2024 are not necessarily indicative of the results to be expected for the full year. The information contained herein should
be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31,
2024 filed with the SEC. Management considers events or transactions that occur after the balance sheet date but before the financial
statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.
Subsequent events have been evaluated through the date of issuance of these financial statements.

6

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

Use of Estimates

The preparation of financial statements is in
conformity with GAAP which requires us to make estimates, judgments and assumptions that affect the financial statements and the notes
thereto. These estimates are based on information available as of the date of the financial statements. On a regular basis, management
evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to:

    ●
    the standalone selling
    price for each distinct performance obligation;

    ●
    the fair value of assets
    acquired, and liabilities assumed for business combinations;

    ●
    the expected credit loss relating to accounts receivable;

    ●
    the determination of contingent consideration amount;
    and 

    ● share based compensation including options and warrants. 

Emerging Growth Company Status

We are an “emerging growth company,”
as defined in the Jumpstart Our Business Startups Act of 2012. We will remain an emerging growth company until the earlier of (i) December
21, 2026 (the last day of the fiscal year